Medtronic's Options Market Flashes Caution as Tariff Headwinds Cloud a Record Year
Published on 06/18/2026 at 06:44 | Redaktion boerse-global.de
The options market is sending a clear warning on Medtronic. Implied volatility on June call options has spiked sharply in recent sessions, suggesting traders are bracing for a significant move in the shares — though the direction remains uncertain. The action centers on the $50 strike calls, where unusual volume and pricing point to either aggressive hedging or outright speculative bets. Zacks Equity Research has responded by downgrading the stock to “Sell,” placing it in the bottom third of its industry group.
The alarm from derivatives comes as Medtronic’s stock continues to struggle. The shares closed at €67.98 on Wednesday, a level that leaves the company nursing a year-to-date loss of roughly 17%. The 200-day moving average of $79.04 remains far out of reach, and the stock is trading nearly 26% below its 52-week high of $91.50 (on a dollar basis, the equivalent high and current price are similarly stretched). A sustainable uptrend has yet to materialize.
Operationally, however, the picture is far more robust. Medtronic just delivered its strongest top-line growth in a decade. For the full fiscal year 2026, revenue climbed 8.4% to $36.4 billion, beating expectations. In the fourth quarter alone, sales reached $9.8 billion, representing organic growth of 6.6%, with the cardiovascular business posting double-digit gains. Operating cash flow also improved. The disconnect between these results and the stock’s trajectory is stark.
Should investors sell immediately? Or is it worth buying Medtronic?
Profitability remains the central concern. For the full year, adjusted operating margin contracted by 130 basis points to 24.4%. Analysts have seized on that weakness. Piper Sandler recently reiterated a neutral rating and a price target of $85, acknowledging operational progress but citing lingering execution risks. The company itself is targeting organic growth of roughly 7% for the current fiscal year and sees adjusted earnings per share rising to as much as $6.00. Investors, though, want hard proof of a margin turnaround before they reward the shares.
The outlook for fiscal 2027 is further complicated by trade policy. Management has flagged that tariffs will add approximately $250 million to production costs in the coming year, with no government reimbursements factored into the forecast. That caution has prompted a wave of target cuts. Bank of America slashed its price objective from $110 to $95, citing inflation and lower hospital utilization rates. Goldman Sachs, Bernstein, and UBS also reduced their targets. On the other side, BTIG upgraded the stock to Buy with a $90 target, praising Medtronic’s consistent organic growth trajectory.
To fuel future expansion, Medtronic has been on an acquisition spree. In the fourth quarter alone, it spent nearly $2 billion on deals, including the purchase of SPR Therapeutics, and earlier moves for CathWorks and Scientia Vascular. One of the most anticipated catalysts is the Hugo robotic surgical system, for which Medtronic has filed for FDA approval in general surgery. The robot is currently cleared only for urological procedures; expanding its label would open up lucrative new markets.
Shareholders, meanwhile, are enjoying a growing dividend — increased for the 49th consecutive year. The next ex-dividend date falls on June 26, with fresh quarterly earnings not due until August. Until then, management faces the challenge of convincing the market that its costly investments and tariff headwinds can still yield a meaningful margin recovery. The options market, for now, is pricing in the suspense.
Ad
Medtronic Stock: New Analysis - 18 June
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
